10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Kallikrein 9 Antibody (Center) Blocking peptide
Synthetic peptide
Catalog # BP6328b

Specification

Kallikrein 9 Antibody (Center) Blocking peptide - Product Information

Primary Accession Q9UKQ9

Kallikrein 9 Antibody (Center) Blocking peptide - Additional Information

Gene ID 284366

Other Names
Kallikrein-9, 3421-, Kallikrein-like protein 3, KLK-L3, KLK9

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP6328b was selected from the Center region of human KLK9. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

Kallikrein 9 Antibody (Center) Blocking peptide - Protein Information

Name KLK9

Cellular Location
Secreted.

Tissue Location
Skin, thymus, trachea, cerebellum and spinal cord.

Kallikrein 9 Antibody (Center) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Kallikrein 9 Antibody (Center) Blocking peptide - Images

Kallikrein 9 Antibody (Center) Blocking peptide - Background

Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. KLK9 is a novel kallikrein with poptential application for diagnosis, monitoring and therapeutics of various cancers including those of the breast, prostate and testis.

Kallikrein 9 Antibody (Center) Blocking peptide - References

Yousef, G.M., et al., Cancer Res. 61(21):7811-7818 (2001).Yousef, G.M., et al., Genomics 65(2):184-194 (2000).Diamandis, E.P., et al., Trends Endocrinol. Metab. 11(2):54-60 (2000).Yousef, G.M., et al., Anticancer Res. 19 (4B), 2843-2852 (1999).